Referrals took less than 90 seconds and increased 26-fold with staff usage of Quit Connect protocol
THURSDAY, April 8, 2021 (HealthDay News) — Implementing the Quit Connect protocol in rheumatology clinics is feasible and increases electronic referrals to a state-run tobacco quit line, according to a study published online April 6 in Arthritis Care & Research.
Christie M. Bartels, M.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues assessed the feasibility and effectiveness of implementation of a staff-driven protocol, Quit Connect, to increase the rate of electronic referrals (e-referrals) from three rheumatology clinics to free, state-run tobacco quit lines. The analysis included 4,078 eligible pre-implementation visits and 523 intervention period visits.
The researchers found that the odds of referral to the tobacco quit line were higher for the postimplementation period compared with the pre-implementation period (unadjusted odds ratio, 26). Similarly, the odds of staff checking patients’ readiness to quit in the next 30 days increased more than 100-fold for the postimplementation period compared with the pre-implementation period (adjusted odds ratio, 132). During the intervention, e-referrals for 71 percent of quit-ready patients occurred in <90 seconds, and nearly one-fourth of referred patients (24 percent) reported a quit attempt.
“Rheumatology visits provide a unique opportunity to address smoking as a chronic modifiable risk factor in populations at high risk for cardiovascular disease, pulmonary disease, and rheumatic disease progression,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Rheumatic Immune-Related AEs With Immune Checkpoint Inhibitors More Severe Than Previously Reported
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Consensus Statements Developed for Rheumatoid Arthritis-Linked Interstitial Lung Disease
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis